Proton Therapy in Japan

Tsunemoto, H; Morita, Shinroku; Ishikawa, Tatsuo; Furukawa, Shigeo; Kawachi, Kiyomitsu; Kanai, Tatsuaki; Ohara, Hiroshi; Kitagawa, Toshio; Inada, Tomohiro

doi:10.2307/3576653

Cited by 22 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RBE incident along particle beam paths, and most notably, at the Bragg peak for protons and carbon ions in radiotherapy has been a key factor when comparing these two types of charged particle therapies. Bragg peak RBE values of proton beams determined experimentally range between 1.0 and 2.1, and therapeutic values are estimated to be of 1.0 or 1.1 depending on the treatment center (15,(18)(19)(20). Reported RBE values for carbon ions in radiotherapy have, in contrast, varied considerably, in part due to the limited number of facilities where these charged particle beams are available to patients worldwide.…”

Section: Comparison Of Cellular Lethality In Dna Repair-proficientmentioning

confidence: 99%

Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions

Genet¹,

Maeda²,

Fujisawa³

et al. 2012

Oncology Reports

View full text Add to dashboard Cite

Charged particle therapy utilizing protons or carbon ions has been rapidly intensifying over recent years. The present study was designed to jointly investigate these two charged particle treatment modalities with respect to modeled anatomical depth-dependent dose and linear energy transfer (LET) deliveries to cells with either normal or compromised DNA repair phenotypes. We compared cellular lethality in response to dose, LET and Bragg peak location for accelerated protons and carbon ions at 70 and 290 MeV/n, respectively. A novel experimental live cell irradiation OptiCell™ in vitro culture system using three different Chinese hamster ovary (CHO) cells as a mammalian model was conducted. A wild-type DNA repair-competent CHO cell line (CHO 10B2) was compared to two other CHO cell lines (51D1 and xrs5), each genetically deficient with respect to one of the two major DNA repair pathways (homologous recombination and non-homologous end joining pathways, respectively) following genotoxic insults. We found that wild-type and homologous recombination-deficient (Rad51D) cellular lethality was dependent on both the dose and LET of the carbon ions, whereas it was only dependent on dose for protons. The non-homologous end joining deficient cell line (Ku80 mutant) showed nearly identical dose-response profiles for both carbon ions and protons. Our results show that the increasingly used modality of carbon ions as charged particle therapy is advantageous to protons in a radiotherapeutic context, primarily for tumor cells proficient in non-homologous end joining DNA repair where cellular lethality is dependent not only on the dose as in the case of more common photon therapeutic modalities, but more importantly on the carbon ion LETs. Genetic characterization of patient tumors would be key to individualize and optimize the selection of radiation modality, clinical outcome and treatment cost.

show abstract

Section: Comparison Of Cellular Lethality In Dna Repair-proficientmentioning

confidence: 99%

Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions

Genet¹,

Maeda²,

Fujisawa³

et al. 2012

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…Technological development of heavy ion systems continued outside of the U.S. with implementation of significant improvements to the first system. For example, a novel beam delivery method for protons called raster scanning, which uses strong magnets to scan a narrow ion beam across the cancer for dose delivery while modulating the beam energy, was developed in Japan in 1984 ( 52 ). GSI developed and implemented raster scanning for CIRT ( 53 ).…”

Section: Heavy Ion Therapy Technology Development Continued After Cli...mentioning

confidence: 99%

National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States

et al. 2022

View full text Add to dashboard Cite

In this review, we attempt to make a case for the establishment of a limited number of heavy ion cancer research and treatment facilities in the United States. Based on the basic physics and biology research, conducted largely in Japan and Germany, and early phase clinical trials involving a relatively small number of patients, we believe that heavy ions have a considerably greater potential to enhance the therapeutic ratio for many cancer types compared to conventional X-ray and proton radiotherapy. Moreover, with ongoing technological developments and with research in physical, biological, immunological, and clinical aspects, it is quite plausible that cost effectiveness of radiotherapy with heavier ions can be substantially improved.

show abstract

“…Japan has two treatment centers which have only been active for a few years but are distinguished by some rather advanced technology [30]. The National Institute of Radiological Sciences (NIRS) at Chiba features the first 3-dimensional beam-scanning system that has actually been used in therapy, though the limited penetration (3.6 em) of the 70-Me V proton beam restricts the kinds of cases that can be treated.…”

Section: Appendix the Hi Story Of Proton Therapy Bernard Gottschalk mentioning

confidence: 99%

Conceptual Design of a Proton Therapy Synchrotron for Loma Linda University Medical Center

Archambeau¹,

Krzich²,

Oleck³

et al. 1986

View full text Add to dashboard Cite

Proton Therapy in Japan

Cited by 22 publications

References 7 publications

Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions

Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions

National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States

Conceptual Design of a Proton Therapy Synchrotron for Loma Linda University Medical Center

Contact Info

Product

Resources

About